VK2735 vs. Retatrutide: Mechanisms and Trial Data (2026)

What is the difference between VK2735 and retatrutide?

VK2735 (Viking Therapeutics) is an investigational GIP/GLP-1 receptor dual agonist peptide. Retatrutide (Eli Lilly, also coded LY3437943) is an investigational triple agonist acting at the GIP, GLP-1, and glucagon receptors. The defining distinction between the two molecules is the third receptor arm: retatrutide engages the glucagon receptor, VK2735 does not. Both have peer-reviewed phase 2 results in the published literature. As of October 16, 2026, VK2735 has two phase 3 trials listed as active and not recruiting and two oral phase 3 trials listed as not yet recruiting on the public registry. Neither compound is an approved medicine.

VK2735 and retatrutide are frequently grouped together as next-generation incretin-based research compounds, but they are not interchangeable members of a single category. Receptor count changes pharmacology, and pharmacology shapes which endpoints a sponsor designs a trial to measure. All compounds discussed on this page are sold for laboratory research use only and are not for human consumption. This article summarises mechanism, published trial reports, and publicly registered development status. It is research and regulatory education, not medical advice, and nothing here describes what either compound does for a person.

What is VK2735?

VK2735 is a peptide agonist at two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It is being developed by Viking Therapeutics as a metabolic research candidate, and it sits in the same broad mechanistic family as tirzepatide, the other well-characterised GIP/GLP-1 dual agonist in the peer-reviewed record. For background on the receptor family itself, see the GLP-1 receptor agonist peptide research hub.

The published clinical record for VK2735 is short but real. A phase 2, randomised, 13-week trial of subcutaneous VK2735 in a weight-management population was published in Obesity (Silver Spring) in 2026 (PubMed 41508550). On the public registry, the phase 1 study NCT05203237 is listed as completed, and the phase 2 VENTURE study NCT06068946 is also listed as completed, both as of October 16, 2026.

The practical point for anyone reading the two literatures side by side is chronological rather than pharmacological: the human data set for VK2735 is younger and thinner than retatrutide's, because the program began publishing later, not because any published comparison has placed one molecule below the other.

What is retatrutide?

Retatrutide is an investigational triple-hormone-receptor agonist from Eli Lilly that activates the GIP, GLP-1, and glucagon receptors within a single peptide. It has the deeper published literature of the two by a wide margin, spanning obesity, type 2 diabetes, hepatic, and body-composition endpoints across several journals.

The anchor citation is the phase 2 obesity trial published in the New England Journal of Medicine in 2023 (PubMed 37366315). A randomised, double-blind phase 2 trial in people with type 2 diabetes appeared in The Lancet the same year (PubMed 37385280), and a further Lancet report on efficacy and safety in type 2 diabetes was published in 2026 (PubMed 42250575).

Beyond glycaemic and body-weight endpoints, a 2024 Nature Medicine paper examined retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD) (PubMed 38858523), and a 2025 phase 2 substudy in Lancet Diabetes & Endocrinology reported effects on body composition in type 2 diabetes (PubMed 40609566).

How do the receptor targets differ, dual versus triple?

The mechanistic gap reduces to one receptor: the glucagon receptor (GCGR). Both molecules engage GLP-1 and GIP receptors; only retatrutide adds glucagon receptor agonism as a third arm. A fuller treatment of that architectural difference sits in the dual versus triple agonist explainer.

Each arm does distinct work in the published mechanistic literature. GLP-1 receptor agonism is the incretin backbone: glucose-dependent insulin secretion from pancreatic beta cells, slowed gastric emptying, and satiety signalling through hypothalamic circuits. GIP receptor agonism supplies a second incretin input, with documented receptor expression and activity in adipose tissue and central nervous system pathways. Glucagon receptor agonism acts primarily on hepatocytes, where the literature describes increased hepatic lipid oxidation and increased energy expenditure.

Those are three different signalling routes converging on overlapping metabolic nodes, and they are not additive in any simple arithmetic sense. Receptor selectivity ratios, relative potency at each receptor, and biased signalling downstream of each receptor all shape the pharmacological profile of a multi-agonist peptide. Two molecules that both activate GLP-1 and GIP receptors can behave quite differently depending on how strongly each receptor is engaged.

The third arm is also why retatrutide's trial portfolio reaches into the liver, while dual-agonist programs typically cluster around body-weight and glycaemic endpoints. The MASLD publication is not an incidental finding; it reflects a trial designed around a hepatic mechanism the molecule possesses by design.

What did the published phase 2 trials report?

Both programs have peer-reviewed phase 2 results, but the two data sets are not symmetrical in duration, population, or endpoint design. That asymmetry is the most frequently misread fact in online comparisons of the two compounds.

The VK2735 phase 2 publication in Obesity (2026) describes a randomised 13-week trial of subcutaneous VK2735 in a weight-management population (PubMed 41508550). The retatrutide phase 2 obesity trial in the New England Journal of Medicine (2023) ran across a substantially longer horizon and reported mean body-weight change versus placebo as its primary endpoint (PubMed 37366315). Additional phase 2 work in type 2 diabetes was reported in The Lancet in 2023 (PubMed 37385280) and again in 2026 (PubMed 42250575).

These results are summarised qualitatively here on purpose. Each study reports outcomes under its own protocol, population, and observation window, and lifting a figure out of one abstract to place beside a figure from another is how unreliable literature reviews get written. The mismatch in trial length alone makes a numeric head-to-head uninterpretable. Readers who need the figures should take them from the primary publications linked above, with the trial design attached.

Which trials are registered, and where do they stand?

As of October 16, 2026, VK2735 has four phase 3 trials visible on ClinicalTrials.gov. VANQUISH-1 (NCT07104500) is listed as active, not recruiting. VANQUISH-2 (NCT07104383), in type 2 diabetes, is also listed as active, not recruiting. Two oral phase 3 trials, SUNRISE-1 (NCT07868835) and SUNRISE-2 (NCT07868939), are listed as not yet recruiting. None of these trials has published outcomes as of that date.

Retatrutide's late-stage footprint is documented differently in the public record. A 2026 paper in Diabetes, Obesity and Metabolism sets out the rationale and design of retatrutide trials in obesity, obstructive sleep apnea, and knee osteoarthritis (PubMed 41090431). That spread of indications signals a broader late-stage strategy than a program oriented solely around body weight and glycaemia.

Asking which program is "further along" produces a misleading answer, because the two are structurally different bets. VK2735 has publicly registered phase 3 trials with named identifiers and trackable recruitment statuses. Retatrutide has the wider published indication rationale and the deeper phase 2 record. Registry stage and depth of peer-reviewed evidence are two different measures of progress, and neither one subsumes the other.

Is VK2735 oral, subcutaneous, or both?

Both. VK2735 is being developed as two separate formulation programs, and that duality is the most distinctive structural feature of the molecule in this comparison.

The subcutaneous program produced the phase 2 publication in Obesity (2026) and the registered VANQUISH phase 3 trials. A separate oral phase 2 study, NCT06828055, is listed as completed as of October 16, 2026, and the SUNRISE-1 and SUNRISE-2 phase 3 trials are registered as oral studies. Retatrutide's published literature to date describes a peptide program without a comparable registered oral phase 3 track.

This matters mechanistically, not only logistically. Peptides face a well-documented bioavailability wall: enzymatic degradation in the gastrointestinal tract and poor paracellular transport across intestinal epithelium mean oral peptide programs generally require permeation-enhancer chemistry and accept markedly lower systemic exposure than parenteral routes. Any cross-formulation comparison within a single molecule therefore has to account for exposure differences before attributing any divergence in outcomes to the molecule itself.

What safety signals did the published trials report?

The published reports for both molecules describe gastrointestinal adverse events as the most commonly reported treatment-emergent findings, which is consistent with the broader incretin receptor agonist literature. The usual mechanistic explanation points to GLP-1 receptor distribution in gastrointestinal tissue and the slowed gastric emptying that is intrinsic to the mechanism.

For retatrutide, the glucagon receptor arm raises questions that dual agonists do not have to answer, because hepatic glucose output, heart rate, and energy expenditure are all downstream considerations once GCGR is engaged. The primary publications describe the adverse events observed under their own protocols; those reports are the appropriate source rather than any secondary summary.

For VK2735, the 13-week phase 2 observation window constrains what can be said at all (PubMed 41508550). Short trials detect frequent, early adverse events well and rare or late ones poorly. A trial reports what its design was powered to detect and nothing beyond that, which is why the registered phase 3 program is the relevant place to look for longer-horizon safety characterisation once it reports.

What is the regulatory status of each compound?

As of October 16, 2026, both VK2735 and retatrutide are investigational compounds. Neither has been approved by the United States Food and Drug Administration, and neither should be described as a therapy or a medicine. They are research compounds moving through the standard clinical development pathway, with trial registrations and peer-reviewed publications forming the public record of that progress.

Investigational status also means there is no approved reference product, no pharmacopoeial monograph, and no regulatory batch oversight comparable to an approved medicine. Published trial reports and registry entries therefore remain the primary verifiable public sources on both compounds, and any marketing language describing either as clinically validated should be treated as a sourcing red flag and checked against the registry directly.

How do researchers study these compounds in preclinical models?

Preclinical characterisation of multi-receptor incretin peptides generally follows a conventional sequence, and the same framework applies to dual and triple agonists alike.

The first layer is in vitro receptor pharmacology. Cell lines engineered to express human GLP-1, GIP, or glucagon receptors are used to measure binding affinity and functional activation, most often through cyclic AMP accumulation assays and β-arrestin recruitment readouts. These assays generate the relative potency profile across receptors that defines a multi-agonist molecule and distinguishes a balanced co-agonist from one weighted heavily toward a single arm.

The second layer is biochemical and stability work: peptide identity confirmation by mass spectrometry and sequencing, chromatographic separation for purity assessment, and degradation studies in plasma or simulated gastrointestinal fluids. For oral formulation research, permeation models using intestinal epithelial cell monolayers are a standard tool for evaluating transport across the epithelial barrier.

The third layer is in vivo work in animal models of metabolic physiology, where investigators track pharmacokinetic parameters, receptor engagement markers, glucose handling, energy expenditure by indirect calorimetry, body composition by imaging or densitometry, and tissue-level endpoints such as hepatic lipid content. Glucagon receptor pharmacology adds hepatic readouts that dual agonist programs do not necessarily include.

Study design, model selection, and endpoint definition are decisions for the investigator and their institutional review process. Nothing on this page constitutes a protocol, and no preparation, measurement, or handling guidance is provided here.

How should researchers compare the two trial programs fairly?

Compare designs before comparing outcomes. Trial duration, baseline population, and endpoint definition are not background detail; they are the variables that determine each reported result.

Four design features decide whether a cross-trial read is defensible. Duration: a 13-week observation window and a multi-quarter window measure different stages of the same biology. Population: obesity cohorts and type 2 diabetes cohorts respond differently to incretin mechanisms, and baseline characteristics shape every reported mean. Endpoint: percentage body-weight change, HbA1c reduction, hepatic fat fraction, and lean-versus-fat mass partitioning are not substitutable measures. Comparator: both phase 2 programs ran against placebo, never against each other.

No registered head-to-head trial of VK2735 against retatrutide appears on the public registry as of October 16, 2026. Every efficacy ranking circulating online is therefore an indirect comparison assembled from separate placebo-controlled studies, and an indirect comparison inherits the confounding of both source trials. Indirect comparisons can be legitimate when the methodology is declared explicitly; they are routinely misleading when it is not.

What is still unknown about VK2735 and retatrutide?

More than most secondary summaries suggest. Neither compound has a published cardiovascular outcomes trial. Neither has long-term durability data past the horizons already reported. And the relative contribution of each individual receptor arm to the composite effects observed has not been isolated in humans for either molecule.

For VK2735, the open questions are duration and scale: the phase 3 VANQUISH and SUNRISE programs will generate the first long-horizon data set, and as of October 16, 2026, none of those trials has reported. For retatrutide, the open question is how the glucagon arm behaves across extended exposure, including hepatic and cardiovascular parameters that short phase 2 windows cannot characterise.

There is also a question the current literature cannot answer: whether three receptors is mechanistically better than two, or simply different. A triple agonist is not automatically superior to a dual agonist. It is a different pharmacological object with a different adverse-event profile and a different set of indications it can plausibly pursue. The dual versus triple agonist comparison covers that distinction in more depth.

Side-by-side: developers, receptor targets, and development stage

The table below summarises verifiable structural facts about each program, drawn from peer-reviewed publications and the public trial registry. It deliberately excludes efficacy figures, because no head-to-head trial exists to make such a comparison valid.

How should the two programs be read overall?

The published record does not support ranking one molecule above the other. One program has a 13-week published phase 2 trial and a registered phase 3 program with trackable statuses. The other has a multi-indication phase 2 portfolio and no published phase 3 outcomes. Those are different kinds of evidence, not different scores on a shared scale.

The glucagon arm makes retatrutide mechanistically broader, and breadth is not the same as superiority; in pharmacology an additional receptor usually brings additional questions along with additional reach. The most useful way to read this comparison is as two development philosophies rather than two efficacy numbers. One program pairs a dual-receptor peptide with two formulation routes. The other pursues a third receptor arm that opens indication territory a pure incretin molecule cannot address, which is why sleep apnea and knee osteoarthritis appear in its published late-stage design rationale (PubMed 41090431). Both questions remain open until the phase 3 readouts and registry status changes arrive, and those will settle the comparison far more reliably than any summary written beforehand. For wider mechanistic context on this receptor family, the GLP-1 receptor agonist research hub collects the underlying pharmacology.